CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication.
Tebas P, Jadlowsky JK, Shaw PA, Tian L, Esparza E, Brennan AL, Kim S, Naing SY, Richardson MW, Vogel AN, Maldini CR, Kong H, Liu X, Lacey SF, Bauer AM, Mampe F, Richman LP, Lee G, Ando D, Levine BL, Porter DL, Zhao Y, Siegel DL, Bar KJ, June CH, Riley JL.
Tebas P, et al. Among authors: richardson mw.
J Clin Invest. 2021 Apr 1;131(7):e144486. doi: 10.1172/JCI144486.
J Clin Invest. 2021.
PMID: 33571163
Free PMC article.
Clinical Trial.